Impax Laboratories Inc Stock as Institutional Investors Exit

May 16, 2018 - By Vivian Currie

Impax Laboratories, Inc. (NASDAQ:IPXL) Logo

Sentiment for Impax Laboratories Inc (NASDAQ:IPXL)

Impax Laboratories Inc (NASDAQ:IPXL) institutional sentiment decreased to 1.26 in Q4 2017. Its down -0.49, from 1.75 in 2017Q3. The ratio worsened, as 91 investment managers increased or started new positions, while 72 sold and decreased their positions in Impax Laboratories Inc. The investment managers in our partner’s database now have: 73.13 million shares, up from 65.84 million shares in 2017Q3. Also, the number of investment managers holding Impax Laboratories Inc in their top 10 positions was flat from 1 to 1 for the same number . Sold All: 27 Reduced: 45 Increased: 55 New Position: 36.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, makes, and markets bioequivalent pharmaceutical products. The company has market cap of $1.31 billion. It operates in two divisions, Impax Generics and Impax Specialty Pharma. It currently has negative earnings. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements.

It closed at $18.3 lastly. It is up 51.97% since May 16, 2017 and is uptrending. It has outperformed by 40.42% the S&P500.

Fosun International Ltd holds 5.63% of its portfolio in Impax Laboratories, Inc. for 3.85 million shares. Maverick Capital Ltd owns 7.33 million shares or 1.54% of their US portfolio. Moreover, Hussman Strategic Advisors Inc. has 0.48% invested in the company for 100,000 shares. The California-based Tcw Group Inc has invested 0.27% in the stock. Menta Capital Llc, a California-based fund reported 60,385 shares.

Impax Laboratories, Inc. (NASDAQ:IPXL) Ratings Coverage

Ratings analysis reveals 38% of Impax Laboratories’s analysts are positive. Out of 8 Wall Street analysts rating Impax Laboratories, 3 give it “Buy”, 0 “Sell” rating, while 5 recommend “Hold”. The lowest target is $18.0 while the high is $27. The stock’s average target of $21.38 is 16.83% above today’s ($18.3) share price. IPXL was included in 8 notes of analysts from December 12, 2017. RBC Capital Markets maintained the shares of IPXL in report on Friday, March 2 with “Hold” rating. The company was maintained on Tuesday, February 27 by Susquehanna. BMO Capital Markets maintained the stock with “Hold” rating in Sunday, April 15 report. The firm has “Hold” rating given on Tuesday, December 12 by Guggenheim. Cowen & Co maintained the shares of IPXL in report on Thursday, March 1 with “Hold” rating. Leerink Swann initiated the stock with “Buy” rating in Tuesday, January 2 report.

Impax Laboratories, Inc. (NASDAQ:IPXL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.